Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Explore Ways to Fix Major Budgeting Mistakes by recalibrating spending, updating goals, and setting up durable budget processes.
17,830 articlesA dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
High-end home sellers confront new commission options after the NAR decoupled buyer and seller fees. This report expl...
Arm Holdings has surged 104% year-to-date, with the AI pivot and AGI CPU driving demand. Smart money sits near a spec...
Mizuho ups UnitedHealth's price target to $440, citing easing medical loss ratio pressures and a turning Medicare Adv...
When a stock climbs 15% after a fund trims its position, investors should look beyond the headline. This article brea...
Canopy Growth has slipped while the market rose. This article breaks down the reasons behind the drop, what it means ...
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Markets shift as the White House cools its push for rate cuts while Kevin Warsh faces inflation constraints. The 10-y...
Coinbase launches three new perpetual contracts that track MarketVector AI, Defense, and China indexes, giving trader...
Fannie Mae updates its crypto mortgage framework with a 250% collateral requirement, reshaping how crypto assets can ...
Apple hits a fresh 52-week high as Services revenue climbs and iPhone demand remains strong. The move fuels a buy, ho...
Through May 2026, CWB rose about 19% year-to-date, underscoring the appeal of convertible bonds as a middle ground be...